ACE and Miyoshi myopathy: The latter might assist oncologists in modifying or interrupting potentially cardiotoxic therapies and make appropriate referrals for cardioprotective medications (e.g., beta-blockers, angiotensin-converting enzyme inhibitors) [8,24]. These interventions aim to preserve cardiac function, reduce the risk of cardiac events, and improve the long-term prognosis of MM survivors [8].